Advanced Drug Delivery Technologies Gain Traction as Oncology Focus Shifts to Improving Existing Therapies

As the costs of oncology drug development continue to rise and regulatory pathways become more complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies, rather than relying exclusively on discovering entirely new drugs. This strategic pivot is drawing attention to nanoparticle delivery systems, intravenous reformulations, and precision pharmacokinetic strategies designed to enhance bioavailability, systemic exposure, tolerability, and dosing consistency of established cancer therapies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of this broader industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company's strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets, rather than relying solely on a single drug candidate. Oncotelic is one of several companies building scalable platforms, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE), and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), which are developing platforms in cancer immunotherapy, genomic medicine, AI/data infrastructure, and cell therapy, respectively.

The importance of this shift lies in its potential to address significant unmet needs in oncology. Many existing cancer drugs, while effective, are limited by poor bioavailability, systemic toxicity, or suboptimal dosing regimens. By reformulating these drugs using advanced delivery systems, companies aim to improve patient outcomes while reducing side effects. For instance, nanoparticle-based delivery can enhance drug accumulation at tumor sites while sparing healthy tissues, potentially improving the therapeutic index. Similarly, AI-driven platforms can optimize dosing schedules and predict patient responses, making treatments more personalized and effective.

The trend also has financial implications. Developing a new drug from scratch can cost billions of dollars and take over a decade, with high failure rates. In contrast, improving an approved drug through advanced delivery may require less time and investment, offering a faster path to market and potentially lower development costs. This approach aligns with the growing interest in platform technologies that can be applied across multiple indications, creating value beyond a single product.

However, challenges remain. Regulatory approval for novel delivery systems requires rigorous demonstration of safety and efficacy, and manufacturing at scale can be complex. Companies must also navigate patent landscapes and reimbursement hurdles. Despite these obstacles, the momentum behind advanced drug delivery in oncology is clear, with multiple players investing in platforms that could reshape treatment paradigms.

The convergence of nanotechnology, AI, and biotechnology is driving this evolution. As Oncotelic and its peers advance their platforms, the focus is on delivering tangible improvements to patients while creating sustainable business models. The coming years will likely see increased collaboration between drug developers and delivery technology specialists, as the industry recognizes that improving how drugs are delivered is as critical as discovering new ones.